Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

558
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
558
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

3.5K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.5K
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

380
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
380
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

346
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
346
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

667
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
667
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.3K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The 10 Commandments of PFO Pathophysiology and Patient Selection.

JACC. Cardiovascular interventions·2026
Same author

Participant Diversity in Stroke-Related Medical Device Trials: Historical Context and Ongoing Challenges.

Stroke (Hoboken, N.J.)·2026
Same author

Patent Foramen Ovale Closure in Stroke and the PASCAL Classification System.

JAMA neurology·2026
Same author

Safety and Efficacy of Percutaneous Access Versus Surgical Cutdown for Thoracic Endovascular Aortic Repair and Transcatheter Aortic Valve Replacement.

Innovations (Philadelphia, Pa.)·2025
Same author

Multicenter Experience With a Novel Real-Time 3-Dimensional Intracardiac Echocardiography Catheter to Guide Interventional Cardiac Procedures.

Journal of the American Heart Association·2025
Same author

Atrial Arrhythmias After PFO Device Closure: Common, Clinically Important, and Preventable?

Circulation·2024
Same journal

Diagnostic Tests for Stage B Heart Failure.

Current cardiology reports·2026
Same journal

Cardioimmunology of Myocarditis: Targeting the IL-1 Pathway.

Current cardiology reports·2026
Same journal

Antithrombotic Management in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation.

Current cardiology reports·2026
Same journal

Transcriptome Reprogramming in Heart Failure: The Hidden Splicing Code.

Current cardiology reports·2026
Same journal

Diagnosis and Management of Loeys-Dietz Syndrome: Evidence Gaps and Future Directions.

Current cardiology reports·2026
Same journal

Correction: Heart Disease in Older Women: Unique Challenges in Diagnosis and Management.

Current cardiology reports·2026
See all related articles

Related Experiment Video

Updated: Feb 11, 2026

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure
07:41

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

Published on: February 8, 2022

4.4K

ASD Closure in Structural Heart Disease.

Dominik M Wiktor1, John D Carroll2

  • 1University of Colorado, Anschutz Medical Campus, Mail Stop B132, Leprino Office Building, 12401 East 17th Avenue, Room 524, Aurora, CO, 80045, USA. dominik.wiktor@ucdenver.edu.

Current Cardiology Reports
|April 19, 2018
PubMed
Summary
This summary is machine-generated.

New data show residual iatrogenic atrial septal defects (iASD) after heart interventions can negatively impact outcomes. This review covers iASD closure indications, new devices, and potential long-term complications.

Keywords:
Atrial septal defect (ASD)Congenital heart diseaseIatrogenic ASDSeptal defect closureStructural heart disease intervention

More Related Videos

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

25.2K
Fluorescent Labeling of Drosophila Heart Structures
11:12

Fluorescent Labeling of Drosophila Heart Structures

Published on: October 13, 2009

14.2K

Related Experiment Videos

Last Updated: Feb 11, 2026

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure
07:41

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

Published on: February 8, 2022

4.4K
Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

25.2K
Fluorescent Labeling of Drosophila Heart Structures
11:12

Fluorescent Labeling of Drosophila Heart Structures

Published on: October 13, 2009

14.2K

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Medical Device Technology

Background:

  • Percutaneous atrial septal defect (ASD) closure is established, but residual iatrogenic ASD (iASD) after left heart interventions is a growing concern.
  • Emerging data link residual iASD to poorer clinical outcomes and increased mortality.
  • Advancements in left-heart structural interventions necessitate a re-evaluation of iASD management.

Purpose of the Study:

  • To review indications for closing iASD following left heart structural interventions.
  • To discuss new-generation closure devices for iASD.
  • To highlight potential late complications and the need for long-term follow-up.

Main Methods:

  • Literature review of recent studies and trials on iASD.
  • Analysis of data concerning residual iASD after large-bore transseptal access.
  • Evaluation of new closure device technologies and their efficacy.

Main Results:

  • Residual iASD is increasingly recognized as a factor affecting clinical outcomes.
  • New closure devices show potential advantages in managing iASD.
  • Understanding and mitigating late complications of percutaneous ASD closure is crucial.

Conclusions:

  • Management of residual iASD is critical in contemporary interventional cardiology.
  • Further research is needed to optimize iASD closure strategies and minimize late complications.
  • Long-term follow-up is essential for patients with iASD after interventions.